VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "AVCR") continues to grow the HealthTab network of pharmacy locations, reaching 532 locations. In 100 of these locations, the Company will be deploying Abbott's ID Now, either in combination with the Afinion 2 or standalone, to support virus detection and assess the demand and effectiveness of infectious disease screening in community pharmacies.
"We are seeing significant demand for HealthTab as the pharmacist scope of practice expansion takes effect and the anticipation of expanded healthcare funding," said Hector Bremner, CEO of Avricore Health Inc. "We look forward to continuing our steady growth and adding value to our offering, such as the new testing options which ID Now brings."
New pharmacy model coming to life
The $51.4 billion CAD (source) Canadian pharmacy business is rapidly changing before our eyes, from being product focused to service focused. Supporting this change have been regulatory changes to expand the scope of practice of the pharmacist to diagnose and treat minor ailments. The 10-year funding agreement being finalized between the federal and provincial governments (source), is anticipated to add necessary funds to support these new areas of work.
Leading the way has been the Pharmacy Walk-In Clinic, where patients can get support for a range of issues that can be assessed by the pharmacist. If the matter is serious, the patient will be referred to a physician, however, for minor ailments, chronic disease management and some prescription renewals, the pharmacist can treat the patient immediately, saving time and healthcare dollars.
One of the important tools for pharmacists is point-of-care testing (POCT), not to mention the critical ability to easily share results with the patient and broader healthcare team. HealthTab, with over 530 locations, which are cloud-connected and give the patient the power to consent to the sharing of this information, makes it quick and easy to collaborate on actions for the patient's health needs.
New capabilities
The Company will be deploying 100 Abbott ID Now instruments in collaboration with Abbott and Shoppers Drug Mart to assess the demand and effectiveness of infectious disease screening in community pharmacies. There is funding today for this testing in some provinces, and it is hoped that the success of the model will encourage the expansion of this critical service across the country.
The addition of new instruments and tests, demonstrates the flexibility and strength of the HealthTab platform as the premier solution for pharmacy based POCT.
HealthTab Market Fast Facts
- Point of Care Testing Market to reach $93.21 billion USD in 2030 (Source)
- Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
- There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
About HealthTab
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
Contact:
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
溫哥華,不列顛哥倫比亞省,2023年3月23日(環球通訊社)AVRICORE Health Inc.(TSXV:AVCR)(“公司“或”AVCR“)繼續擴大HealthTab藥房地點網路,達到532個地點。在其中100個地點,公司現在將部署雅培公司的ID,無論是與Afinion 2結合使用還是單獨部署,以支持病毒檢測並評估社區藥店傳染病篩查的需求和有效性。
Avricore Health Inc.首席執行官Hector Bremner說:“隨著藥劑師執業範圍的擴大生效,以及對醫療保健資金擴大的預期,我們看到對HealthTab的巨大需求。”我們期待著繼續我們的穩步增長,並為我們的產品增加價值,例如ID現在帶來的新測試選項。“
新的藥房模式即將面世
價值514億加元(來源)的加拿大製藥業務正在我們眼前迅速變化,從專注於產品轉向專注於服務。支持這一變化的是法規改革,以擴大藥劑師診斷和治療小病的執業範圍。聯邦政府和省級政府之間正在最後敲定的為期10年的供資協定(來源)預計將增加必要的資金,以支持這些新的工作領域。
藥房無預約診所一直處於領先地位,患者可以在那裡獲得一系列問題的支持,這些問題可以由藥劑師進行評估。如果病情嚴重,患者會被轉介給醫生,但對於小病、慢性病管理和一些處方續期,藥劑師可以立即治療患者,節省時間和醫療費用。
藥劑師的重要工具之一是護理點測試(POCT),更不用說與患者和更廣泛的醫療團隊輕鬆共享結果的關鍵能力。HealthTab有超過530個位置,這些位置都是雲連接的,使患者有權同意共享這些資訊,從而可以快速輕鬆地就患者的健康需求採取行動進行協作。
新功能
該公司將與雅培和購物者藥市合作,部署100臺雅培ID Now儀器,以評估社區藥店對傳染病篩查的需求和有效性。目前在一些省份有資金用於這項測試,希望該模式的成功將鼓勵這項關鍵服務在全國範圍內推廣。
新儀器和測試的增加,證明瞭HealthTab平臺作為基於POCT的藥房的首要解決方案的靈活性和實力。
HealthTab市場快訊
- 2030年關注點測試市場規模將達到932.1億美元(來源)
- 預計到2030年,近1360萬加拿大人將患有糖尿病或糖尿病前期,其中許多人未確診(來源)
- 超過三分之一的美國人,約8800萬人,患有糖尿病前期(來源)
- 每年有近16萬20歲及以上的加拿大人被診斷出患有心臟病,通常是在心臟病發作後才被診斷出來。(來源)
- 加拿大有1萬多家藥店,美國有8.8萬家藥店,英國有近1.2萬家。
關於HealthTab
HealthTab是一種交鑰匙醫療保健測試解決方案,它將一流的醫療保健點技術與基於雲的安全平臺相結合,以解決緊迫的全球健康問題。只需手指刺傷的幾滴血,該系統就能在現場生成實驗室準確的結果,並即時報告數據。測試菜單包括多達23個用於篩查和管理慢性疾病的關鍵生物標記物,如糖尿病和心臟病(例如,HbA1c、血脂譜、EGFR)。HealthTab最近還增加了細菌和病毒檢測功能,如鏈球菌和新冠肺炎。
HealthTab的網路模式與當今製藥行業的任何模式都不同。它使知識淵博和值得信賴的藥劑師在初級保健提供方面發揮更大的作用,同時使患者能夠更好地控制自己的健康。它還減少了成本和等待時間,並提供了許多潛在的收入來源,包括設備租賃和耗材、直接訪問測試、疾病預防和管理計劃、贊助的健康計劃、分散的臨床試驗、真實世界數據(RWD)集,以及通過API的第三方應用程式集成。
關於Avricore Health Inc.
Avricore Health Inc.(多倫多證券交易所股票代碼:AVCR)是一家藥房服務創新者,專注於獲取和開發旨在推動藥房向前發展的早期技術。通過其全資子公司HealthTab的旗艦產品,該公司的使命是通過在社區藥店創建世界上最大的快速檢測設備網路,使每個人都更容易獲得可操作的健康資訊。
聯繫方式:
Avricore Health Inc.
首席執行官赫克託·佈雷姆納,電話:604-773-8943
郵箱:Info@avricoreHealth.com
有關前瞻性陳述的注意事項
本新聞稿中涉及Avricore Health對未來的預期、計劃、意圖或戰略的資訊是前瞻性陳述,不是事實,涉及許多風險和不確定因素。Avricore Health通常使用諸如“展望”、“將會”、“可能”、“可能”、“仍然”、“將要”、“計劃”、“相信”、“可能”、“預期”、“打算”、“預期”、“估計”、“未來”、“定位”、“潛在”、“專案”、“保留”、“計劃”、“計劃”、“設置為,“受制於”、“即將到來”和類似的表達,以幫助識別前瞻性陳述。在本新聞稿中,前瞻性陳述包括有關以下方面的陳述:配售完成及其預期時間和公司預期配售收益的使用;HealthTab平臺向藥劑師和患者提供的獨特功能。前瞻性陳述反映了當時對Avricore Health管理層的預期、信念、假設、估計和預測。本新聞稿中的前瞻性陳述是基於截至本新聞稿發佈之日Avricore Health獲得的資訊。前瞻性陳述在作出時被認為是真實的,最終可能被證明是不正確的。這些陳述不是對Avricore Health未來業績的保證,會受到一些風險、不確定因素和其他因素的影響,其中一些因素是Avricore無法控制的,可能會導致實際結果與當前的預期大不相同,包括但不限於:未能滿足監管要求;市場變化;經濟狀況的潛在下滑;以及Avricore公開提交的檔案中描述的其他風險因素。這些前瞻性陳述僅在發表之日發表,公司沒有義務公開更新這些陳述,以反映新的資訊或未來事件或情況的發生,除非法律另有要求。
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。